Applied Therapeutics Inc. entered into a Securities Purchase Agreement for a private placement with accredited investors, expecting to receive gross proceeds of approximately $100 million for research and development and general corporate purposes. They also announced the acceptance of the New Drug Application for govorestat for the treatment of Classic Galactosemia by the FDA, with a target action date of August 28, 2024.